Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
3.15
Dollar change
0.00
Percentage change
0.00
%
Index- P/E- EPS (ttm)-2.38 Insider Own48.78% Shs Outstand18.88M Perf Week-1.56%
Market Cap76.45M Forward P/E- EPS next Y-1.29 Insider Trans0.00% Shs Float12.43M Perf Month-8.30%
Income-43.66M PEG- EPS next Q-0.41 Inst Own28.43% Short Float0.10% Perf Quarter41.89%
Sales35.35M P/S2.16 EPS this Y29.07% Inst Trans-0.09% Short Ratio0.53 Perf Half Y146.09%
Book/sh-1.66 P/B- EPS next Y19.57% ROA-75.42% Short Interest0.01M Perf Year81.03%
Cash/sh0.79 P/C3.97 EPS next 5Y- ROE-775.14% 52W Range1.10 - 4.19 Perf YTD45.83%
Dividend Est.- P/FCF- EPS past 5Y-17.26% ROI- 52W High-24.81% Beta0.52
Dividend TTM- Quick Ratio0.64 Sales past 5Y-5.10% Gross Margin34.73% 52W Low186.34% ATR (14)0.24
Dividend Ex-Date- Current Ratio0.73 EPS Y/Y TTM0.43% Oper. Margin-60.52% RSI (14)43.87 Volatility4.40% 7.67%
Employees54 Debt/Eq- Sales Y/Y TTM-28.14% Profit Margin-123.51% Recom1.00 Target Price5.50
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q-75.61% Payout- Rel Volume0.12 Prev Close3.15
Sales Surprise-10.31% EPS Surprise-131.58% Sales Q/Q-53.61% EarningsMar 07 AMC Avg Volume24.44K Price3.15
SMA20-5.40% SMA50-11.35% SMA20038.12% Trades Volume3,001 Change0.00%
Date Action Analyst Rating Change Price Target Change
Nov-02-20Initiated Truist Buy $20
Nov-02-20Initiated Piper Sandler Overweight $20
Nov-02-20Initiated Cowen Outperform $20
Nov-02-20Initiated Cantor Fitzgerald Overweight $20
Mar-07-24 09:53PM
04:05PM
Feb-22-24 04:05PM
Feb-20-24 10:37AM
Jan-10-24 04:05PM
08:00AM Loading…
Dec-18-23 08:00AM
Nov-13-23 04:05PM
Nov-09-23 08:30AM
Nov-06-23 04:05PM
Oct-18-23 08:00AM
Sep-20-23 08:30AM
Sep-19-23 08:36AM
Sep-18-23 04:08PM
Sep-08-23 08:30AM
Sep-06-23 04:05PM
08:30AM Loading…
Aug-30-23 08:30AM
Aug-21-23 09:42AM
Aug-15-23 05:21AM
Aug-14-23 04:05PM
Jul-31-23 04:05PM
Jul-26-23 03:29PM
Jul-17-23 04:05PM
Jul-13-23 04:30PM
May-19-23 01:45PM
08:15AM
May-13-23 08:17AM
May-11-23 09:58AM
05:51AM
May-10-23 04:05PM
May-03-23 04:05PM
10:42AM Loading…
10:42AM
Apr-20-23 04:30PM
Apr-17-23 06:11AM
Apr-05-23 09:55AM
Mar-27-23 06:26AM
Mar-23-23 06:08AM
Mar-22-23 04:01PM
08:30AM
Mar-20-23 12:01PM
08:00AM
Mar-15-23 04:05PM
Feb-27-23 08:15AM
Jan-31-23 08:00AM
Jan-26-23 12:00PM
09:40AM
Jan-21-23 09:58AM
Jan-09-23 08:15AM
Dec-15-22 08:00AM
Dec-10-22 07:38AM
Dec-01-22 09:04AM
Nov-30-22 04:08PM
Nov-21-22 04:05PM
Nov-16-22 06:00AM
Nov-14-22 05:25PM
04:01PM
Nov-07-22 04:05PM
07:40AM
Oct-25-22 09:47AM
Oct-24-22 08:00AM
Oct-18-22 04:05PM
Oct-11-22 04:35PM
07:44AM
Aug-26-22 09:00AM
Aug-17-22 04:05PM
Aug-16-22 01:53PM
Aug-14-22 10:16AM
Aug-11-22 04:05PM
03:09PM
Aug-10-22 06:56PM
Aug-09-22 05:58PM
Jul-28-22 04:05PM
Jul-20-22 09:40AM
Jun-27-22 04:15AM
Jun-21-22 04:05PM
Jun-01-22 08:50AM
May-09-22 05:25PM
04:05PM
May-02-22 08:21AM
Apr-25-22 04:05PM
Apr-12-22 04:05PM
Apr-04-22 08:00AM
Mar-31-22 06:50PM
Mar-11-22 08:30AM
Mar-07-22 06:40AM
Mar-04-22 09:28AM
Mar-03-22 06:25PM
04:01PM
Feb-23-22 04:01PM
Feb-17-22 04:01PM
Feb-14-22 12:00PM
09:40AM
Jan-18-22 08:45AM
Jan-11-22 10:00AM
Dec-27-21 04:01PM
Dec-08-21 05:31PM
Dec-06-21 06:59AM
Nov-15-21 04:05PM
Nov-09-21 05:25PM
04:01PM
Nov-02-21 03:02PM
Elutia, Inc. operates as a biotechnology company. It develops biologic products to improve compatibility between medical devices and the patients who need them. The firm operates through the following segments: Device Protection, Women's Health, Orthobiologics and Cardiovascular. The Device Protection segment includes biological envelope that remodels into systematically connected, vascularized tissue for the long-term pocket protection of certain cardiac and neurostimulator implantable electronic vehicles. The Women's Health segment includes pre-hydrated, human acellular dermal matrix, or HADM, that is designed to enable rapid integration, cellular repopulation and rapid revascularization at the surgical site. The Orthobiologics segment includes a variety of viable matrices, produced with a proprietary process that is designed to protect and preserve native bone cells and reduce programmable cell death, for use in bone repair and fusion procedures. The Cardiovascular segment includes a portfolio of extracellular matrices that retain the natural composition of collagen, growth factors and proteins for use in vascular and cardiac repair and pericardial closure. The company was founded by Kevin L. Rakin and Charles Randal Mills on August 6, 2015 and is headquartered in Silver Spring, MD.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ferguson MatthewCHIEF FINANCIAL OFFICERMar 08 '24Option Exercise0.001,2880121,807Mar 14 04:43 PM
Mills C RandalPRESIDENT AND CEOApr 27 '23Option Exercise0.0044,947048,008Apr 28 05:31 PM